solo para uso en investigación

PD 98059 MEK inhibidor

Name: PD 98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (518 reviews)

Cat. No.S1177

PD98059 es un inhibidor de MEK no competitivo con ATP con una IC50 de 2 μM en un ensayo libre de células, inhibe específicamente la activación de MAPK mediada por MEK-1; no inhibe directamente ERK1 o ERK2. PD98059 es un ligando para el receptor de hidrocarburos arilo (AHR) y funciona como un antagonista de AHR.

PD 98059 MEK inhibidor Chemical Structure

Estructura química

Peso molecular: 267.28

Saltar a

Control de calidad

Lote: Pureza: 99.92%

99.92

Dianas relacionadas	ERK p38 MAPK Raf JNK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Otros MEK Inhibidores	PD0325901 (Mirdametinib) U0126-EtOH PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 SL-327 BIX 02188

Cultivo celular, tratamiento y concentración de trabajo

Líneas celulares	Tipo de ensayo	Concentración	Tiempo de incubación	Formulación	Descripción de la actividad	PMID
TE4	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
MKN7	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
OE19	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NCI-N87	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
KATOIII	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC3	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC2	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
SGC-7901	Apoptosis Assay	20 μM	24 h		inhibits CP-mediated apoptosis	24241351
MG-63	Function Assay	20 μM	0.5 h		blocks the CH-induced phosphorylated ELK1 protein expression	24239640
ARPE-19	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
CRL-2302	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
MCF-7	Apoptosis Assay	20 μM	1 h		increases caspase-9 enzyme activity	24216289
MCF-7	Function Assay	20 μM	1 h		abolishes expression of phosphorylated ERK co-treatment with conjugate	24216289
7402	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
HT-29	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
DLD-1	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
7721	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
SGC7901	Apoptosis Assay	50 μM	24/48/72 h	DMSO	induces apoptosis combined with JAK2 shRNA	24178240
SMMC7721	Function Assay	25/50 μM	24 h		suppresses the expression of p-Akt or p-ERK1/2	24168056
MCF-7	Growth Inhibition Assay	10 μM	48h	DMSO	reverses BNF-induced cell cycle arrest	24163404
Caco-2	Function Assay	50 μM	48h	DMSO	enhances the mRNA levels of SCNN1A,FXYD3, LCT, LOX, HIF3A, ZG16, PDE6A and LGALS16 genes co-treated with Dex	24161695
HAECs	Function Assay	10 μM	1 h		attenuates TNF-α-stimulated ICAM-1 and VCAM-1 expression	24134657
Ca9-22	Function Assay	3 μM	1 h		abolishes the ability of HbR to induce IL-8 production	24126532
Ca9-22	Function Assay	3 μM	1/2 h		reduces HbR-induced ATF-2 phosphorylation	24126532
AGS	Function Assay	10 μM	0.5 h		inhibits the upregulation of the IL-8 gene	24106166
Caco-2	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
A549	Function Assay	50 μM	2 h		blocks ERK phosphorylation mediated by 1,2-NQ	24067727
HPMC	Function Assay	10 μM	48 h		reverses the changes in cell morphology induced by HGPDS	24042838
HCT-8	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
HPMC	Apoptosis Assay	10 μM	24 h		reverses decrease in cell viability induced by HGPDS	24042838
MGC803	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
SGC7901	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
G292	Apoptosis Assay	30 μM	2 h		restores capsaicin-induced cell death	24012930
COLO205	Apoptosis Assay	10/20/40 μM	24 h		induces DNA ladder formation	24019108
BxPC-3	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HPAF-II	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HepG2	Function Assay	40 μM	6/12 h		inhibits the increase of p-ERK1 and p-c-Jun protein expression by PL	23942851
HL-60	Apoptosis Assay	50 μM	1 h		rescues BA145 mediated apoptosis	23948751
LNCaP	Function Assay	10 μM	1 h		decreases the EGF upregulated p-YB-1	23838318
HUVECs	Function Assay	25 μM	1 h		increase NF-κB p65 nuclear translocation	23901008
HL60	Function Assay	20 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
NB4	Function Assay	10 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
EPOR/CR3	Function Assay	50 μM	3 h		reduces EPO and/or IL-3-induced the tyrosine phosphorylation	23820731
HUASMCs	Function Assay	10 μM	24 h		inhibits Ang II-induced ERK1/2 phosphorylation level	23816468
HUASMCs	Function Assay	10 μM	24 h		diminishes Ang II-caused SOCS3 mRNA and protein expression	23816468
SGC7901	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
MKN45	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
SGC7901	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
MKN45	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
SGC7901	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
MKN45	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
BxPC-3 cells	Growth Inhibition Assay	20 μM	0.5 h		inhibits VEGF-A-regulated HUVEC growth and tube formation induced by PAR-2 AP	23764046
NB4	Apoptosis Assay	10/20/60 μM	1.5 h	DMSO	decreases cell viability co-treated	23735541
HepG2	Function Assay	20 μM	24 h		inhibits the HO-1 protein expression co-treated	23707609
HUVECs	Apoptosis Assay	2/4 μM	24/48 h		induces cell death	23707520
KG-1	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
AML 1#	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
A2780	Function Assay	20 μM	1 h		blocks DTCD-induced DR5 expression	23696862
KYSE30	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE5	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE1	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE3	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
KYSE30	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE1	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE4	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
HT29	Function Assay	10 μM	2 h		inhibits of JAK2, ERK1/2 and STAT3 phosphorylation	24265293
HepG2	Apoptosis Assay	20 μM	24 h		inhibits ERK1/2 phosphorylation and enhances VB1-induced apoptosis	24247909
HepG2	Function Assay	20 μM	2 h		enhances VB1-induced FOXO3a transcriptional activity	24247909
MC-3	Apoptosis Assay	10 μM	24 h		potentiated MESC-induced apoptosis in cells	24270523
Raji	Function Assay	10 μM	1 h		blocks hsBAFF induced Erk1/2 phosphorylation	24269630
Raji	Growth Inhibition Assay	10 μM	1 h		inhibits the basal or hsBAFF-stimulated cell proliferation and viability	24269630
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits thrombin-induced C/EBPβ Thr235 phosphorylation	24277696
HCSMCs	Growth Inhibition Assay	10 μM	24 h		blocks FABP4-induced HCASMC proliferation	24312381
PANC-1	Function Assay	20 μM	48 h		inhibits the expression of Δ6D in response to the PPARδ agonist	24294133
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits the thrombin-induced IL-8/CXCL8-Luc activity	24277696
SW480	Function Assay	10 μM	20 h	DMSO	suppresses the CRT activity	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	inhibits Wnt-induced β-catenin/TCF4 activity and nuclear β-catenin accumulation	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	suppresses the CRT activity	24324366
HL-60	Function Assay	10/20 μM	1 h		inhibits the N. chinensisextract induced differentiation into granulocytes	24357020
HL-60	Function Assay	2 µM	16 h	DMSO	inhibits the association of pS621 Raf-1 and NFATc3, and the RA-induced phosphorylation of nuclear NFATc3	24330068
HeLa	Function Assay	50 μM	0.5 h		blocks TRX-1 nuclear migration and TXNIP down-regulation	24376827
HUVECs	Function Assay	10 μM	1 h		inhibits the HDL reduced COX-2 expression and PGI-2 release	24385109
MCF-7	Function Assay	10 μM	10/30 min		reduces the UTP-dependent ERK phosphorylation	24390819
HGC-27	Apoptosis Assay	1 µM	1 h		suppresses RAD001 plus MK-2206-induced cell viability loss	24416349
PC3	Apoptosis Assay	50 μM	0.5 h		inhibits MHY-449-induced apoptosis	24424889
HPAEpiCs	Function Assay	30 μM	1 h		inhibits TNF-α stimulated p42/p44 MAPK phosphorylation	24441870
BeWo	Function Assay	10 μM	2 h		inhibits ERK1/2	24433846
A498	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
NHBE	Function Assay	2/20 μM	2 h		attenuates IL-33 stimulated CXCL8/IL-8 secretion	24479526
A375	Cell Invasion Assay	10–20 µM	24 h		reduces melanoma cell invasion	24466036
HBMEC	Function Assay	10 μM	1 h		blocks VEGF-induced EphA2 expression	24458982
HCT-15	Function Assay		1 h		attenuates PGE2-induced phosphorylation of Erk	25431425
HCT-15	Apoptosis Assay		1 h		abolishes the protective effects of PGE2 against curcumin-induced apoptosis	25431425
786-O	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
HepG2	Growth Inhibition Assay	20 μM	24 h		suppresses TGF-β1-induced cell proliferation and invasion	25560488
SW480	Function Assay	20 μM	1 h		reduces the expression of ATF3 protein	25447816
MDA-MB-231	Function Assay	25 μM	2-3 h		decreases p-ERK1/2 and S100A4 expression	25555875
HepG2	Function Assay	10 μM	5 h		blocks phosphorylated MAPKs induced by exogenous TGF-β1	25560488
MCF-7	Function Assay	10 μM	1 h		inhibits IL-18-enhanced cell migration	25727011
H1355	Function Assay	25 μM	1 h		blunts the B[a]P-induced increase in phospho-Chk1 and phospho-ERK expression	25769181
PC12	Function assay				Inhibition of nerve growth factor-mediated MAP kinase activity in human PC12 cells, IC50 = 2 μM.	18077363
HT-29	Antiproliferative assay		5 days		Antiproliferative activity against human HT-29 cells after 5 days by WST1 assay, IC50 = 4 μM.	25078316
IEC6	Function assay		5 mins		Inhibition of MEK1/2 in rat IEC6 cells assessed as reduction in ERK1/2 loop phosphorylation dosed 30 mins before to stimulation with 10% serum for 5 mins by immunoblotting method, IC50 = 4.2 μM.	25078316
NG 108-15	Function assay				Concentration required to abolish MAPK activity in mouse neuroblastoma and rat glioma hybrid NG 108-15 cells, Activity = 10 μM.	15537354
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with JNK inhibitor SP600125 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK2 inhibitor U0126 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK1 inhibitor PD98059 for 1 hr before compound addition by Western blot analysis	21345685
HeLa	Function assay	20 uM	3 hrs		Inhibition of ERK1/2 phosphorylation in human HeLa cells at 20 uM after 3 hrs by Western blotting analysis	23570615
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
TC32	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
MDA-MB-231	Function assay	50 uM			Downregulation of MMP2 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
MDA-MB-231	Function assay	50 uM			Downregulation of MMP9 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad

Peso molecular	267.28	Fórmula	C₁₆H₁₃NO₃	Almacenamiento (Desde la fecha de recepción)	3 años-20°Cpolvo
Nº CAS	167869-21-8	Descargar SDF		Almacenamiento de soluciones madre	1 año-80°Cen disolvente 1 mes-20°Cen disolvente
Sinónimos	N/A			Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

Solubilidad

In vitro
Lote:

DMSO : 46 mg/mL (172.1 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Water : Insoluble

Ethanol : Insoluble

Calculadora de Molaridad

Masa	Concentración	Volumen	Peso molecular
=	×	×

Calculadora de Dilución Calculadora de Peso Molecular

In vivo Lote:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	4%DMSO 1 30%PEG300 2 5%Tween80 3 61%ddH2O Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 40 μL 25 mg/ml clarified DMSO stock solution to 300 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 610 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

Dosis: mg/kg Peso promedio de los animales: g Volumen de dosificación por animal:μL Número de animales:

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH₂O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción

Características	Does not inhibit c-Raf phosphorylated MEK1.
Targets/IC₅₀/Ki	AhR (Cell-free assay) 1 μM MEK1 (Cell-free assay) 2 μM
In vitro	PD98059 inhibe tanto la MEK1 basal como una MEK parcialmente activada producida por la mutación de la serina en los residuos 218 y 222 a glutamato (MEK-2E) con una CI50 de 2 μM. Este compuesto no inhibe los homólogos de MAPK JNK y P38. Es altamente selectivo contra MEK, ya que no inhibe una serie de otras actividades quinasa, incluyendo la quinasa Raf, la quinasa dependiente de cAMP, la proteína quinasa C, v-Src, la quinasa del receptor del factor de crecimiento epidérmico (EGF), la quinasa del receptor de insulina, la quinasa del receptor de PDGF y la fosfatidilinositol 3-quinasa. Este inhibidor inhibe la activación de MAPK estimulada por PDGF y la incorporación de timidina en células 3T3 con una CI50 de ~10 μM y ~7 μM, respectivamente. Previene potentemente la activación de MEK1 por Raf o MEK quinasa con una CI50 de 4 μM, e inhibe débilmente la activación de MEK2 por Raf con una CI50 de 50 μM. Esta sustancia química no inhibe la activación de los homólogos de MEK MKK4 y RK quinasa que participan en las cascadas de quinasas estimuladas por el estrés y la interleucina-1 en células KB y PC12, ni la activación de la p70 S6 quinasa por insulina o factor de crecimiento epidérmico en células Swiss 3T3. Bloquea completamente la diferenciación de células PC12 inducida por el factor de crecimiento nervioso (NGF) sin alterar la viabilidad celular. Este compuesto inhibe la proliferación de células RAW264.7 en el cultivo que contiene RANKL de manera dosis-dependiente, lo que resulta en una disminución aparente de las células TRAP-positivas.
Ensayo de quinasa	Actividad inhibidora de MEK in vitro
Ensayo de quinasa	Se ensaya la incorporación de ³²P en la proteína básica de la mielina (MBP) en presencia de proteínas de fusión de glutatión S-transferasa (GST) que contienen la MAPK de 44 kDa (GST-MAPK) o la MEK de 45 kDa (GST-MEK1). Los ensayos se realizan en 50 μL de 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP que contienen 10 μg de GST-MEK1, 0.5 μg de GST-MAPK y 40 μg de MBP. Después de la incubación a 30°C durante 15 minutos, las reacciones se detienen mediante la adición de tampón de muestra SDS de Laemmli. La MBP fosforilada se resuelve mediante SDS/PAGE al 10%.
In vivo	El tratamiento de ratones 30 minutos antes de la isquemia cerebral focal con PD98059 protege contra el daño, lo que resulta en una disminución del volumen del infarto. El pretratamiento con este compuesto 30 minutos antes y luego junto con inyecciones horarias de ceruleína durante 3 horas mejora significativamente la pancreatitis aguda inducida por ceruleína, según el peso húmedo pancreático y la histología. La administración de este químico (10 mg/kg) en ratones 1 hora después de la carragenina provoca una reducción en todos los parámetros de inflamación medidos.
Referencias	[1] https://pubmed.ncbi.nlm.nih.gov/7644477/ [2] https://pubmed.ncbi.nlm.nih.gov/7499206/ [3] https://pubmed.ncbi.nlm.nih.gov/7775407/ [4] https://pubmed.ncbi.nlm.nih.gov/12237315/ [5] https://pubmed.ncbi.nlm.nih.gov/10536014/ [6] https://pubmed.ncbi.nlm.nih.gov/12370536/ [7] https://pubmed.ncbi.nlm.nih.gov/20074457/ [8] https://pubmed.ncbi.nlm.nih.gov/11254111/ [9] https://pubmed.ncbi.nlm.nih.gov/17161815/ [10] https://pubmed.ncbi.nlm.nih.gov/14506750/ [11] https://pubmed.ncbi.nlm.nih.gov/14506750/ [12] https://pubmed.ncbi.nlm.nih.gov/9495809/

Aplicaciones

Métodos	Biomarcadores	Imágenes	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT p-JNK / JNK / Cyclin D1 p-HER2 / HER2 MMP9 / XIAP / VEGF		17482134

Soporte técnico

Instrucciones de manipulación

Tel: +1-832-582-8158 Ext:3

Si tiene alguna otra consulta, por favor deje un mensaje.

Preguntas frecuentes

Pregunta 1:
How to formulate this inhibitor for i.p. injection?

Respuesta:
You can prepare the stock of this compound by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):